DS
SMMT icon

David Shaw’s Summit Therapeutics SMMT Stock Holding History

David Shaw’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-55,000
Closed -$981K – 4706
2024
Q4 		$981K Buy
+55,000
New +$1.07M ﹤0.01% 3215

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

David Shaw's SMMT Position: Q2 2026 in Review

David Shaw reduced its Summit Therapeutics (SMMT) stake by 45% in Q2 2026, selling an estimated $17.7M and leaving 1,243,556 shares worth $18.1M. The position accounts for 0.01% of the portfolio, ranked #1350.

David Shaw first reported a position in SMMT in Q2 2021 and has held it in 12 quarters since. The position peaked at $42.5M in Q1 2026. 241 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • David Shaw held 1,243,556 shares of Summit Therapeutics worth $18.1M as of Q2 2026.
  • David Shaw sold 998,673 Summit Therapeutics shares in Q2 2026, an estimated $17.7M.
  • Summit Therapeutics made up 0.01% of David Shaw's portfolio in Q2 2026, its #1350 holding.
  • David Shaw first reported a position in Summit Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • David Shaw's Summit Therapeutics position peaked at $42.5M in Q1 2026.
  • 241 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.